Billionaire Bob Duggan's new antibiotic play fails a Phase III trial, and investors aren't happy
Bob Duggan — the billionaire investor famous for turning Pharmacyclics from a penny stock to a $20 billion company — placed a handsome bet on the company’s new antibiotic for C. difficile infection last year, scooping up a majority stake and naming himself CEO in hopes of turning a profit in a field largely abandoned by Big Pharma.
But on Monday, a Phase III failure sent the company’s stock spiraling in premarket trading — and now, Duggan says he’s looking to raise more cash.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.